NICE Turns Down Avastin For Yet Another Indication In Draft Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.’s NICE issues draft guidance recommending against use of Avastin for first recurrence of platinum-sensitive advanced ovarian cancer, citing evidence and cost-effectiveness issues.
You may also be interested in...
Expanded Colorectal Cancer Claim Moves Avastin Toward Continuous Use
FDA approves use of Genentech’s bevacizumab for second-line treatment of metastatic colorectal cancer patients who have progressed on a first-line, Avastin-containing chemotherapeutic regimen.
NICE Rejects Roche’s Avastin In Advanced Ovarian Cancer
The U.K.'s health care cost regulator says it wouldn't recommend Roche's Avastin as a first-line treatment for advanced ovarian cancer along with standard chemotherapy, on grounds it doesn’t offer value for money.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: